Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2Sarcoma 1Myeloid 1Lymphoid 1Genitourinary 1CNS 1Breast 1

Conditions

Breast Neoplasms 3Neoplasms 2Neoplasm Metastasis 2Urologic Neoplasms 1Thyroid Neoplasms 1Soft Tissue Neoplasms 1Sarcoma 1Recurrence 1Pharyngeal Neoplasms 1Neurofibromatosis 2 1Neoplasms, Mesothelial 1Mouth Neoplasms 1Lymphangioleiomyomatosis 1Erdheim-Chester Disease 1Endocrine Gland Neoplasms 1Castleman Disease 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 2Fluorodeoxyglucose F18 2temsirolimus 1nabiximols 1motexafin gadolinium 1fluoromisonidazole 1brodalumab 1belinostat 1Valproic Acid 1Taxes 1Sirolimus 1Rubidium-82 1Ritonavir 1Radiotherapy 1Psychology, Positive 1Polymerase Chain Reaction 1Nivolumab 1Methods 1Magnetic Resonance Spectroscopy 1Indinavir 1Immunohistochemistry 1Immunoglobulin G 1Gene Expression Profiling 1Fluorouracil 1Fluorescent Antibody Technique 1Flow Cytometry 1FPP(RGD)2 1Drug Therapy 1Doxorubicin 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mouth Neoplasms × Valproic Acid × Breast × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡